PFIZER ONCOLOGY: NEARLY TWO DECADES OF

PFIZER ONCOLOGY:NEARLY TWO DECADES OFTRANSFORMING CANCER CAREPfizer’s commitment to oncology began nearly two decades ago. Today, our extensive portfolio of cancer therapies continuesto break boundaries in cancer care with comprehensive and cutting-edge treatment options that have one clear mission:addressing the diverse needs of people across the cancer care community.Click on the timeline below to learn more about key Pfizer Oncology milestones. Learn more about Pfizer Oncology athttp://www.pfizer.com/research/therapeutic 990s2007–201020151Oncology

1990s19951991Celltech entered into a collaboration withWyeth for the research, developmentand commercialization of antibodycytotoxic conjugates as novel oncologytreatments. This led to the discovery ofnew hematology drugs. Pfizer mergedwith Wyeth in 2009.1Parke-Davis started the project for anew breast cancer drug. Parke-Daviswas acquired by Warner Lambert, whichwas later acquired by Pfizer in 2000.Synthesis of the drug occurred in 2001.2References: 1. Pharma Intelligence. Accessed September 7, 2018. 2. Science Magazine. Accessed September 7, 2018.2Oncology

2000–2006200620052000Pfizer grew its investments inoncology, dedicating almost 1 billion to the developmentof new cancer medicines.The FDA approved Pfizer’s treatmentfor advanced renal cell carcinoma andgastrointestinal stromal tumors underpriority review, marking the first time theFDA approved a new oncology productfor two indications simultaneously.6Pfizer acquired Warner-Davis/Parke-Lambertand its research into the development of aselective cyclin-dependent kinases 4 and 6(CDK 4/6) inhibitor.320062003Pfizer finalized a deal to merge with PharmaciaCorporation, expanding Pfizer’s product portfoliointo oncology with medicines for colorectal,and breast cancers as well as the transfer of aninvestigational tyrosine kinase inhibitor (TKI).4,5Pfizer acquired RinatNeuroscience Corp, whichcurrently serves as Pfizer’sprimary immuno-oncologyresearch facility due to itsstrength in biotherapeuticsand expertise inimmuno-biology.7References: 3. McCain J. Pharmacy and Therapeutics. 2015;40(8):511-520. 4. 2003: Pfizer and Pharmacia Merger. Pfizer. http://www.pfizer.com/about/history/pfizer pharmacia.Accessed November 28, 2016. 5. Pfizer Drug Targets Gene Flaw to Shrink Lung Tumors (Update1). Bloomberg Businessweek. Accessed November 28, 2016. 6. Pfizer Press Release.Issued January 26, 2006. Accessed October 16, 2017. 7. Pfizer Press Release. Issued April 7, 2016. Accessed May 7, 2018.3Oncology

2007–20102007Pfizer has 15 oncologycompounds in clinicaldevelopment, and conductedover 200 oncology studies.2007200820092010The FDA approved Pfizer’s secondcompound for the treatment ofadvanced renal cell carcinoma.820082007Pfizer completed the acquisition ofWyeth, which included the transferof approved and investigationalmedicines in hematology.11Pfizer announced theestablishment of a newBusiness Unit focusedsolely on oncologyin its WorldwidePharmaceutical Group.9FivePrime and Pfizerentered an oncology anddiabetes collaboration.10Pfizer launched its Global Health Partnerships (GHP) program,a comprehensive approach to help tackle the global cancerepidemic, and committed to investing approximately 47 million over four years (2008-2011) in 32 promisingcancer and tobacco control organizations in 46 countries.The European Commissionapproved Pfizer’s treatmentfor unresectable or metastatic,well-differentiated pancreaticneuroendocrine tumors (NET)following disease progressionin adults, representing the firsttreatment to be approved forpatients with pancreatic NET in25 years.12References: 8. FDA Press Release. Issued May 30, 2007. Accessed May 9, 2018. 9. Pfizer Press Release. Issued May 14, 2008. Accessed November 28, 2016. 10. Pfizer Press Release.Issued May 20, 2008. Accessed May 7, 2018. 11. Pfizer Completes Acquisition Of Wyeth. Pfizer Press Release. Issued October 15, 2009. Accessed November 28, 2016. 12. Pfizer Press Release.Issued December 2, 2010. Accessed October 16, 2017.4Oncology

2011–2014201420122011The FDA approved an additionalPfizer treatment for patients withpreviously treated advanced renalcell carcinoma.142013The FDA approved Pfizer’s treatmentfor ALK-positive metastatic non-smallcell lung cancer, representing a newchapter in biomarker-driven therapyfor lung cancer.13Pfizer collaborated with Cellectis todevelop chimeric antigen receptorT-cell (CAR-T) immunotherapies.17Pfizer’s cyclin-dependent kinases 4 and 6(CDK 4/6) inhibitor received BreakthroughTherapy designation by the FDA.1620142012The FDA approved Pfizer’s treatment forpatients with previously treated chronicmyelogenous leukemia. This approval markedthe third new Pfizer Oncology medicine to beapproved by the FDA in a 13-month span.15Pfizer entered into an alliancewith Merck KGaA to jointlydevelop and commercializean investigational anti-PD-L1IgG1 monoclonal antibody.18References: 13. Pfizer Press Release. Issued August 26, 2011. Accessed November 28, 2016. 14. Pfizer Press Release. Issued January 27, 2012. Accessed on October 16, 2017.15. Pfizer Press Release. Issued September 4, 2012. Accessed November 28, 2016. 16. Pfizer Press Release. Issued April 10, 2013. Access November 28, 2016.17. Pfizer Press Release. Issued June 18, 2014. Accessed December 15, 2016. 18. Pfizer Press Release. Issued November 17, 2014. Accessed November 28, 2016.5Oncology

2015Pfizer and Servier entered into a collaboration agreement toco-develop and commercialize an allogeneic chimeric antigenreceptor T-cell (CAR-T) immunotherapy asset developedthrough Cellectis’s TALEN gene-editing technology.19The FDA approvedPfizer’s CDK 4/6 inhibitor,making it the first CDK4/6 inhibitor to beapproved in the U.S.20Pfizer and Hospira entered into adefinitive merger agreement underwhich Pfizer will acquire Hospira,the world’s leading provider ofinjectable oncology drugs andinfusion technologies and a globalleader in biosimilars.21The FDA granted BreakthroughTherapy designation for Pfizer’s ALKinhibitor in a second rare form ofnon-small cell lung cancer.22Pfizer and Merck KGaA’s investigationalcompound is granted BreakthroughTherapy designation in metastaticMerkel cell carcinoma.24Pfizer entered into a long-termagreement with Thermo Fisher Scientificto develop and commercialize a multimarker, universal next-generationsequencing (NGS) oncology test that willserve as a companion diagnostic (CDx)for non-small cell lung cancer acrossmultiple drug development programs.25Pfizer’s investigationalcompound for acutelymphoblastic leukemiais granted BreakthroughTherapy designation.23References: 19. Cellectis, Servier and Pfizer Press Release. Issued November 19, 2015. Accessed January 4, 2017. 20. Pfizer Press Release. Issued February 3, 2015. Accessed November 28, 2016.21. Pfizer Press Release. Issued February 5, 2015. Accessed November 28, 2016. 22. Pfizer Press Release. Issued April 21, 2015. Accessed December 12, 2016. 23. Pfizer Press Release.Issued October 19, 2015. Accessed November 28, 2016. 24. Pfizer and Merck Press Release. Issued November 18, 2015. Accessed December 12, 2016. 25. Thermo Fisher Scientific Press Release.Issued November 18, 2015. Accessed 29, 2017.6Oncology

2016The FDA approved Pfizer’s treatment foran additional indication in ROS1-positiveadvanced non-small cell lung cancer.27Pfizer completed the acquisition of Medivation,expanding Pfizer’s oncology product portfolioto include an approved product in prostatecancer and two investigational medicines.26References: 26. Pfizer Press Release. Issued September 28, 2016. Accessed November 28, 2016. 27. Pfizer Press Release. Issued March 11, 2016. Accessed March 24, 2017.7Oncology

2017The FDA approved Pfizer’s treatment for adults with newly diagnosedCD33-positive acute myeloid leukemia (AML), and adults and childrentwo years and older with relapsed or refractory CD33-positive AML. Thistreatment is the first therapy with an indication that includes pediatric AML.32Pfizer joined the CancerMoonshot initiative toaccelerate cancer research.Pfizer launched novel patientassistance programs, This isLiving with Cancer and PfizerOncology Together , to helppatients manage life with cancer.28The FDA approvedPfizer’s treatment foradults with relapsedor refractory B-cellprecursor acutelymphoblastic leukemia.31The FDA expanded the indication for Pfizer’s chronicmyeloid leukemia treatment to include newlydiagnosed patients, marking the third U.S. hematologyapproval for Pfizer in the span of five months.34This indication was later approved by the EuropeanCommission in April 2018.35The FDA approved a newindication expanding the useof Pfizer’s treatment to include theadjuvant treatment of adult patients athigh risk of recurrent renal cell carcinomafollowing nephrectomy (surgical removalof the cancerous kidney). This is the firstFDA-approved adjuvant treatment forrenal cell carcinoma.33The FDA approved Pfizer and Merck KGaA’streatment for metastatic Merkel cell carcinoma,making it the only FDA-approved treatmentfor this patient population and Pfizer’s firstapproved immunotherapy.29 This product waslater approved for a second indication in locallyadvanced or metastatic urothelial carcinoma.30The FDA grantedBreakthrough Therapydesignation to Pfizerand Merck KGaA’scombination treatmentin advanced renal cellcarcinoma.36References: 28. Pfizer Press Release. Issued October 5, 2017. Accessed May 7, 2018. 29. Pfizer Press Release. Issued March 23, 2017. Accessed on March 24, 2017. 30. Pfizer Press Release. Issued May 9,2017. Accessed on May 7, 2018. 31. Pfizer Press Release. Issued August 17, 2017. Accessed on September 29, 2017. 32. Pfizer Press Release. Issued September 1, 2017. Accessed on September 29, 2017.33. Pfizer Press Release. Issued November 17, 2017. Accessed on April 19, 2018. 34. Pfizer Press Release. Issued December 19, 2017. Accessed on April 20, 2017. 35. Pfizer Press Release. Issued April 23,2018. Accessed on May 7, 2018. 36. Pfizer Press Release. Issued December 21, 2017. Accessed on April 20, 2018.8Oncology

2018Pfizer and Allogene announced that the two companieshave entered into an asset contribution agreementfor Pfizer’s portfolio of assets related to allogeneicchimeric antigen receptor T-cell (CAR T) therapy.37The FDA approved two biosimilars in three months withone being the first and only biosimilar erythropoiesisstimulating agent to be approved in the U.S.38, 39The FDA approved four treatments for advanced formsof cancer in two months, including two in metastaticnon-small lung cancer, one in metastatic breast cancer,and one in acute myeloid leukemia.40, 41, 42, 43Pfizer adds biosimilars portfolio to theoncology business unit to bring the totalnumber of approved medicines to 17.44Reference: 37. Pfizer Press Release. Issued April 3, 2018. Accessed on April 20, 2018. 38. Pfizer Press Release. Issued May 15, 2018. Accessed on February 20, 2019.39. Pfizer Press Release. Issued July 20, 2018. Accessed on February 20, 2019. 40. Pfizer Press Release. Issued September 27, 2018. Accessed on January 30, 2019.41. Pfizer Press Release. Issued October 16, 2018. Accessed on January 30, 2019. 42. Pfizer Press Release. Issued November 2, 2018. Accessed on January 30, 2019.43. Pfizer Press Release. Issued November 21, 2018. Accessed on January 30, 2019. 44. Pfizer Press Release. Issued July 31, 2018. Accessed on February 18, 2019.9Oncology

8 . 3 27 9 218 9 Pfizer Press Release 14 28 28 216 10 Pfizer Press Release. 2 28 7 218 11 Pfizer Completes Acquisition Of Wyeth. Pfizer Press Release. Issued October 15, 2009. Accessed November 28, 2016. 12 Pfizer Press Rel